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Rapport de synthèse 
Grâce au développement de moyens de transport modernes, de plus en plus d'enfants et 
d'adolescents se rendent en haute altitude dans le cadre de leurs loisirs. Le mal aigu des montagnes 
est une complication fréquente des séjours en haute altitude. Ses symptômes en sont des maux de 
tête, une fatigue, des troubles du sommeil, des nausées et des vertiges. La vitesse d'ascension, 
l'altitude maximale atteinte, une susceptibilité individuelle ainsi qu'une acclimatation antérieure à 
l'altitude sont tous des facteurs influant sur le risque de développer un mal aigu des montagnes et sur 
sa sévérité. 
Bien que très fréquente chez l'adulte, nous ne possédions, au moment d'entreprendre l'étude faisant 
l'objet de cette thèse, que peu de données solides concernant la prévalence de cette affection chez 
l'enfant ainsi que sur son évolution au cours du temps. 
Cette étude a pour but de mesurer la prévalence du mal aigu des montagnes, et son évolution au 
cours du temps au sein d'un groupe d'enfants et d'adolescents dans des conditions contrôlées. C'est 
à dire en éliminant l'influence de facteurs confondants tels que l'importance de l'exercice physique 
fourni ou une différence dans la vitesse d'ascension. 
Pour ce faire nous avons évalué la présence de mal aigu des montagnes dans un groupe de 48 
garçons et de filles âgés de 11 à 17 ans en bonne santé habituelle, n'ayant jamais séjourné en haute 
altitude au préalable. Afin d'évaluer la présence ou non de mal aigu des montagnes nous avons utilisé 
une version française du « Lake Louise Score ». 
Les mesures furent effectuées 6,24 et 48 heures après l'arrivée à la station de recherche de la 
Jungfraujoch située à 3'450m. L'ascension a consisté en un trajet de train durant 2h30. 
Nos observations montrent que la prévalence du mal aigu des montagnes durant les 3 premiers jours 
ne dépasse jamais les 25%. Elle est similaire pour les deux sexes et diminue au cours du séjour. 
(17% après 24 heures, 8% après 48 heures) Aucun sujet n'a dû être évacué à une altitude inférieure. 
Cinq sujets ont eu besoin de recourir à un traitement symptomatique et y ont bien répondu 
Les résultats de cette étude démontrent que dans le groupe d'âge étudié, après une ascension rapide 
en haute altitude, la prévalence du mal aigu des montagnes est relativement faible, ses manifestations 
cliniques sont bénignes et, lorsqu' elles sont présentes, se résolvent rapidement. Ces observations 
suggèrent que pour la majorité des enfants et des adolescents en bonne santé et non habitués à 
l'altitude, un séjour en haute altitude 'ne présente pas de risque et une prophylaxie pharmacologique 
du mal aigu des montagnes n'est pas nécessaire. 
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What's Known on This Subject What This Study Adds 
Although AMS represents an important problem for adults traveling to high altitude, 
litt le is known about the prevalence and time course of this disease in older children and 
adolescents. 
ln this controlled study, we found that symptoms of AMS in older children and adoles-
cents were relatively mild and resolved rapidly without treatment. We suggest that 
children planning to ascend rapidly to 3500 m may not need AMS prophylaxis. 
ABSTH/Kf 
OBJECTIVE. Acute mountain sickness is a frequent and debilitating complication of 
high-altitude exposure, but there is little information on the prevalence and time 
course of acute mountain sickness in children and adolescents after rapid ascent by 
mechanical transportation to 3500 m, an altitude at which major tourist destinations 
are located throughout the world. 
METHODS. We performed serial assessments of acute mountain sickness (Lake Louise 
scores) in 48 healthy nonacclimatized children and adolescents (mean ± SD age: 
13.7 ± 0.3 years; 20 girls and 28 boys), with no previous high-altitude experience, 
6, 18, and 42 hours after arrivai at the Jungfraujoch high-altitude research station 
(3450 m), which was reached through a 2.5-hour train ascent. 
RESULTS. We found that the overall prevalence of acute mountain sickness during the 
first 3 days at high altitude was 37.5%. Rates were similar for the 2 genders and 
decreased progressively during the stay (25% at 6 hours, 21%at18 hours, and 8% 
at 42 hours). None of the subjects needed to be evacuated to lower altitude. Five 
subjects needed symptomatic treatment and responded well. 
CONCLUSION. After rapid ascent to high altitude, the prevalence of acute mountain 
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sickness in children and adolescents was relatively low; the clinicat manifestations were benign and resolved rapidly. 
These findings suggest that, for the majority of healthy nonacclimatized children and adolescents, travel to 3 500 m 
is safe and pharmacologie prophylaxis for acute mountain sickness is not needed. Pediatrics 2009; 123: 1-5 
---·---· -·-------·--------------· -----------··--· -··---------------------------·-·----------····--------------·--
FACILITATED BY MODERN transportation systems, travel to high-altitude destinations has become increasingly popular. Therefore, large numbers of persans, including increasing numbers of children and adolescents, are 
being exposed to high altitude-related n~edical risks. Among the altitude-related medical problems, acute mountain 
sickness (AMS) is by far the most common. Its main symptoms are headache, anorexia and nausea, fatigue, dizziness, 
and sleep disturbance. It affects otherwise-healthy persans of ail ages who ascend to altitudes of >2500 m. The rate 
of ascent, the absolute altitude reached, individual susceptibility, and previous acclimatization are important 
determinants of the incidence and severity of AMs.1 The importance of the first 2 factors is illustrated by the 
observation that, after rapid ascent by plane from 1300 m to a tourist destination located at 3740 m, 84% of an adult 
population was reported to suffer from AMS. 2 More recently, age also has been proposed as a risk factor. 3 It has been 
suggested that the incidence and severity of AMS may be inversely related to climbers' age; brain swelling may be 
better tolerated by elderly individuals because of the smaller brain/cranial vault volume ratio.4•5 There are few clinical 
data to substantiate this speculation, 6 however, and there is no information from a controlled study on the prevalence 
and time course of AMS in adolescents after rapid ascent by mechanical transportation to altitudes of ~3 500 m, at 
which major tourist destinations are located throughout the world. Therefore, we performed serial assessments of 
AMS in 48 healthy nonacclimatized children and adolescents with no previous high-altitude experience who rapidly 
ascended from 568 m to 3450 m by train and then spent 48 hours at that altitude. 
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METHODS 
Study Group 
Our study group consisted of 48 healthy Swiss children 
and adolescents (age: mean ± SD: 13.7 ± 0.3 years; 
range: 10-17 years; 20 girls and 28 boys). AU except 2 
(who lived at 1100 m) were living at altitudes of <800 
m. None of the participants had slept at altitudes of 
> 1500 min the 2 months preceding the study, none had 
ever spent a night at altitudes of >2000 m, and none was 
taking any medication at the time of the study. The 
experimental protocol was approved by the institutional 
review board on human investigation of the Centre Hos-
pitalier Universitaire Vaudois. AU parents provided writ-
ten informed consent. 
The participants ascended to the high-altitude re-
search station with a 2.5-hour train ride that took them 
from 568 m to an altitude of 3450 m. They then spent 2 
days and 2 nights at the laboratory. AU participants 
received the same diet, and care was taken to ensure 
adequate fluid intake. On the day of arrivai, the partic-
ipants rested quietly and visited the research station and 
the adjacent installations. In the afternoon of the second 
day, all participants made an easy 2- to 2.5-hour walk to 
the Monchsjoch hut located at 3650 m. On the morning 
before descent, the subjects had no particular physical 
activity. The presence of AMS was evaluated 6, 18, and 
42 hours after arrivai at the high-altitude research lab-
oratory. 
Symptoms of AMS 
On the evening of the day of arrivai and on the 2 
following mornings, symptoms of AMS were assessed 
with a French version of the Lake Louise self-assessment 
questionnaire/ under the supervision of a trained exam-
iner. Briefly, for each of the 5 items (headache, gastro-
intestinal symptoms, fatigue, dizziness, and sleep distur-
bance ), the participants noted a score between 0 and 3, 
with O indicating the absence of the symptom, 1, mild 
symptoms, 2, moderate symptoms, and 3, severe inca-
pacitating symptoms. For children <12 years of age, a 
verbally adapted version of the score was used (Lake 
Louise age-adjusted symptom score). Clinicat symptoms 
(change in mental status, ataxia, and the presence of 
edema) were assessed by one of us (Dr Bloch) immedi-
ately after completion of the questionnaire. Participants 
were considered suffering from AMS if they were expe-
riencing headache and scored 2:3 on the self-assessment 
questionnaire (the maximal scoré for the questionnaire 
being 15). 
Statistical Analyses 
Statistical analyses were performed by using the paired, 
1-tailed, Student's t test and the McNemar test. Data are 
expressed as mean ± SD. A P value of <.05 was consid-
ered to indicate statistical significance. 
RESULTS 
AU subjects completed the daily questionnaires (Table 
1). Figure 1 shows that the majority of cases of AMS 
( 66 % ) developed during the first few hours at high 
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altitude. On the evening of the day of arrivai, 12 (25%) 
of the 48 subjects suffered from headache and had symp-
tom scores of 2:3 (range: 3-7). Over the subsequent 36 
hours at high altitude, the prevalence of AMS decreased 
progressively and significantly (P < .05). On the morn-
ing of day 2, AMS had resolved for 7 of the 12 partici-
pants who suffered from AMS on the evening of the first 
day, it persisted for 5 of those participants, and it devel-
oped in 5 new subjects; therefore, 10 (21 %) of the 48 
subjects met the criteria for AMS (range of scores: 3-7). 
On the morning of day 3, AMS had disappeared for all 
except 3 subjects, and it developed in 1 new subject; 
therefore, only 4 subjects (8%) still had symptoms of 
AMS (range of scores: 3-5). The overall prevalence of 
AMS was 37.5%, and rates were similar for boys and 
girls; 7 (35%) ofthe 20 girls and 11 (39%) of the 28 boys 
had an AMS score of 2:3 on 2: 1 occasion. Independent of 
whether AMS was present, fatigue ( day 1) and fatigue 
together with sleep disturbances ( days 2 and 3) were the 
leading complaints of the participants. 
Among the subjects who suffered from AMS, the 
disease was relatively mild; the mean scores were 4.0 ± 
1.2 on day 1, 5.0 ± 1.5 on day 2, and 3.7 ± 1.0 on day 
3. Only 1 of the 48 subjects scored 3 (severe incapaci-
tating symptoms) on 1 of the items of the questionnaire. 
Finally, 5 subjects suffering from AMS were given a 
single dose of paracetamol for headache. The symptoms 
responded well to this symptomatic treatment. In the 
clinicat assessment part of the Lake Louise scoring sys-
tem, the signs also were mild and decreased significantly 
during the stay; the mean score was 0.3 ± 0.6 (range: 
0-2) on day 1, 0.1 ± 0.4 (range: 0-1) on day 2, and 
0.1 ± 0.4 (range: 0-1) on day 3 (P < .05, day 1 versus 
day 3). 
DISCUSSION 
With steadily increasing numbers of children and ad-
olescents arriving by modern transportation systems 
at tourîst destinations located at altitudes comparable 
to the one used in our study, it becomes important to 
have reliable data on the prevalence, incidence, and 
time course of AMS in this age group. Here we show 
that, in healthy nonacclimatized children and adoles-
cents who were brought rapidly to 3450 m, the overall 
prevalence of AMS during the first 3 days at this 
altitude was 37.5%. Moreover, the prevalence de-
creased at each measurement, the symptoms were 
relatively mild, and the majority of cases resolved 
wîthout treatment. These data indicate that, for chil-
dren and adolescents wîth no previous high-altitude 
experience, the clinicat manifestations of AMS are 
benign and the time course is brief. 
Two thirds of the cases of AMS developed during 
the first few hours at high altitude. The prevalence of 
AMS was maximal on the evening of the day of arrivai 
and then decreased progressively during the next 2 
days at high altitude. Among those who were sick, the 
Lake Louise scores represented mild illness and the 
symptoms responded well to symptomatic treatment. 
None of the subjects needed to be evacuated to a lower 
altitude or experîenced progression of AMS to high-
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FIGURE 1 
a 
Total Day 1 Day2 Day3 
Total and day-to-day prevalence of AMS after rapid ascent by train to 3450 m among 48 
healthy nonacclimatized children. AMS was assessed 6 hours after arrivai (day 1) and on 
the morning of the next 2 days.' P < .05, day 1 versus day 3. 
altitude cerebral edema, the most dangerous compli-
cation of AMS. None of the subjects developed high-
altitude pulmonary edema. The trend for higher AMS 
scores on day 2 than on day 1 was related to the fact 
that, on day 2, insomnia contributed to the symptom 
scores; this symptom did not corne into account on 
day 1 because the subjects had spent the night at 
home. Insomnia was related to altitude rather than 
sleeping in a dormitory setting, because the subjects 
slept in small bedrooms. Consistent with the rather 
low scores on the self-assessment questionnaire, the 
scores for the clinical assessment part of the Lake 
Louise scoring system also were low. This finding sug-
gests that, for adolescents suffering from mild to mod-
erate AMS, clinical evaluation does not seem to pro-
vide important additional information. 
The prevalence of AMS among adolescents in the 
present study, although still representing a significant 
burden of disease, was considerably lower than the 
rate ( 84%) reported for an adult population after ar-
riva! by airborne transportation at an altitude that was 
comparable to the one in the present study. 2 The rate 
was similar to that reported for an adult population 
studied at much lower altitude. 8 This finding might 
suggest that young age does not represent a risk factor 
for AMS. The prevalence of AMS did not differ be-
tween female and male participants, which suggests 
that gender does not play a role for adolescents. As in 
adults, physical effort may represent a risk factor for 
AMS in children and adolescents. One of the strengths 
of the present study was that physical effort was 
highly standardized, with only mild physical effort on 
the day of arriva! and moderate effort on the second 
day. This amount of physical effort may be quite com-
parable to that of children and adolescents arriving at 
high-altitude tourist destinations after rapid ascent 
with mechanical transportation. Therefore, the data 
on the prevalence, clinical manifestations, and time 
course of AMS in our controlled study probably also 
apply to this type of pediatric population. 
For adults planning rapid ascent to high altitudes, 
current guidelines propose prophylaxis for AMS with 
drugs that may have significant adverse effects. 1 On the 
basis of the present findings, we suggest that, for chil-
dren and adolescents with no history of moderate/severe 
AMS who plan to ascend rapidly to the study altitude, 
pharmacologie prophylaxis for AMS may not be needed 
and the use of pharmacologie agents should be restricted 
to the treatment of symptoms (mainly headache) if they 
appeai., 
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